Gujarat Themis Biosyn Ltd (GUJTHEM)
₹429.90
Mkt cap
₹5,354 Cr
P/E ratio
110.00
P/B
16.28
Div yield
0.16%
ROE
17.40%
ROCE
17.90%
EPS (TTM)
₹3.91
Book value
₹26
52W range
227–470
Sector
Healthcare
Price history
Previous close
Incorporated in 1981, Gujarat Themis Biosyn Ltd manufactures and sells finished Active Pharmaceutical Ingredients products by fermentation process [1]
NSE GUJTHEMBSE 506879
Health check
Constructive
ValuationExpensive
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−8.51% from high₹430
₹227+89.47% from low₹470
Current
₹429.90
Prev close
₹412.00
Day
+4.34%
Price performance
1D
+4.34%
1W
+1.82%
1M
+20.78%
3M
+7.17%
6M
+49.63%
1Y
+11.85%
YTD
−1.22%
Financials
Revenue, profit & margin
P/E ratio
110.0×
GUJTHEM is 224% above the sector median of 34.0×
GUJTHEM110.0×
Sector median34.0×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 50 | 40 | 39 | 42 | 39 | 35 | 40 | 38 | 36 | 42 | 43 | 44 | 44 | |
| Expenses | 26 | 23 | 21 | 21 | 20 | 19 | 21 | 22 | 22 | 21 | 22 | 25 | 23 | |
| Operating Profit | 24 | 17 | 18 | 21 | 19 | 15 | 19 | 16 | 14 | 21 | 21 | 19 | 21 | |
| OPM % | 47% | 42% | 46% | 50% | 48% | 44% | 48% | 42% | 39% | 49% | 49% | 44% | 48% | |
| Other Income | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 1 | 0 | 1 | 0 | 1 | 0 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | |
| Depreciation | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 2 | 3 | 4 | 4 | 4 | |
| Profit before tax | 24 | 17 | 18 | 21 | 18 | 14 | 17 | 16 | 12 | 19 | 17 | 14 | 15 | |
| Tax % | 26% | 26% | 26% | 24% | 26% | 26% | 25% | 25% | 25% | 24% | 26% | 24% | 27% | |
| Net Profit | 18 | 13 | 13 | 16 | 13 | 11 | 13 | 12 | 9 | 14 | 12 | 11 | 11 | |
| EPS in Rs | 1.63 | 1.15 | 1.19 | 1.46 | 1.21 | 0.97 | 1.19 | 1.10 | 0.83 | 1.31 | 1.14 | 1.00 | 1.02 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.64% · closed higher next day 1 of last 1
| Q1FY27 | |
|---|---|
| Broadcast | 7 Aug '26 |
| Earnings day | −1.64% |
| +1 day | +1.56% |
| +5 days | −3.63% |
| +15 days | +13.58% |
| +30 days | — |
| Filing | XBRL |
Corporate actions
Last 6 monthsNo recent corporate actions
Dividends, splits, and bonuses in the last six months show up here.
Results analysis
Shareholding
as of Jun 202670.87%Promoter
Promoters70.87%0.01
FIIs1.76%0.04
DIIs1.17%
Public26.18%0.03
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,899.00 | 36.07 | 4,55,634 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,100.00 | 81.09 | 2,41,576 | 0.33% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,857.00 | 82.80 | 1,84,745 | 0.78% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| CIPLA | ₹1,385.00 | 31.26 | 1,11,888 | 0.94% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| ZYDUSLIFE | ₹1,120.00 | 22.95 | 1,11,720 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| LAURUSLABS | ₹1,840.00 | 90.93 | 99,417 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,110.00 | 16.20 | 96,483 | 0.85% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| GUJTHEM | ₹411.35 | 109.98 | 5,354 | 0.16% | 11 | +22.19% | 44 | +22.08% | 17.86% |
| Median: 158 Co. | ₹421.50 | 33.96 | 2,277 | 0.08% | 13 | +30.25% | 164 | +18.67% | 14.96% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts32
Credit ratings6
Announcements5
Reg. 34 (1) Annual Report. 4 SepBusiness Responsibility and Sustainability Reporting (BRSR) 4 Sep - Filed FY25-26 integrated annual report and BRSR; details major capacity expansion and acquisitions.Shareholders Meeting - AGM On 30.09.2026 4 Sep - AGM notice includes 335.01 crore preferential issue for MBJ acquisition, plus promoter loans and dividends.Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 2 Sep - Promoter shareholding passively reduced after 2,11,86,440 shares QIP allotment on 28.08.2026.Board Meeting Outcome for Outcome Of The Board Meeting Held On 01-09-2026 1 Sep - Board approved preferential issue of 82.1 lakh shares at Rs 408, raising up to Rs 335 crore.